TRICS III: Restrictive Transfusion Was Noninferior to Liberal Use in Patients Who Undergo Cardiac Surgery

A large study conducted in 19 countries has found that a policy of restrictive red-cell transfusion during cardiac surgery is just as safe and effective as more liberal policies.

TRICS III: la transfusión restrictiva resultó no inferior a la liberal en pacientes que reciben cirugía cardíaca

TRICS III enrolled 5243 patients and was presented at the American Heart Association (AHA) Scientific Sessions and published simultaneously in the New England Journal of Medicine (NEJM). Patients were randomized to a restrictive protocol (start transfusion if hemoglobin levels <7.5 g/dL, starting at the time of anesthesia induction) or a liberal protocol (start at hemoglobin <9.5 g/dL in the operating room or <8.5 g/dL in the recovery ward).


Read also: Study Confirms Lead Shields Protect Cath Lab Staff from Radiation Exposure”.


The primary composite endpoint (death, infarction, renal failure requiring dialysis, or stroke) was reached by 11.4% of patients in the restrictive group vs. 12.5% in the liberal group.

 

Secondary endpoints such as ICU length of stay, infection, ventilation days, and acute renal failure, among others, were no different between strategies either.


Read also: Though on the Rise, the Transradial Approach to Primary PCI Remains Underused”.


TRICS III provides evidence that a restrictive red-cell transfusion strategy is effective and safe.

 

Original title: Restrictive Liberal Red-Cell Transfusion for Cardiac Surgery.

Reference: Mazer CD et al. N Engl J Med. 2017;Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...